Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery

Journal of Surgical Oncology

Volumn 100, Issue 4, 2009, Pages 311-316

  Yonemura, Yutaka ^a,i   Endou, Yoshio ^b   Shinbo, Masaya ^c   Sasaki, Takuma ^d   Hirano, Masamitu ^e   Mizumoto, Akiyoshi ^e   Matsuda, Takayuki ^e   Takao, Nobuyuki ^e   Ichinose, Masumi ^e   Mizuno, Mitsukuni ^e   Miura, Masahiro ^f   Ikeda, Makoto ^g   Ikeda, Satoshi ^g   Nakajima, Gou ^g   Yonemura, Jou ^a   Yuuba, Takafumi ^h   Masuda, Seiji ^h   Kimura, Hironobu ^a   Matsuki, Nobuo ^a  

^a NPO Organization to Support Peritoneal Dissemination Treatment   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c Kishiwada Tokushukai Hospital   (Japan)

^d AICHI GAKUIN UNIVERSITY   (Japan)

^e Kusatsu General Hospital   (Japan)

^f OITA UNIVERSITY   (Japan)

^g Department of Surgery   (Japan)

^h Towakai Hospital   (Japan)

ⁱ Peritoneal Dissemination Program   (Japan)

Author keywords

CDDP; Docetaxel; Gastric cancer; Intraperitoneal chemotherapy; Peritoneal dissemination; TS 1

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROPYRIMIDINE DERIVATIVE; TS 1; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; BONE MARROW SUPPRESSION; CANCER CELL; CANCER CHEMOTHERAPY; CARCINOMATOUS PERITONITIS; CONFERENCE PAPER; CYTOLOGY; CYTOREDUCTIVE SURGERY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; PATIENT COMPLIANCE; PERITONEUM CELL; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; STOMACH CANCER; STOMATITIS; SURGICAL TECHNIQUE; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SELECTION; PERITONEAL NEOPLASMS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS;

EID: 69749120079     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21324     Document Type: Conference Paper

References (28)

1. Yonemura Y, Wu CC, Fukushima N, et al.: Randomized clinical trial of D2 and extended para-aortic lymphadenectomy in patients with gastric cancer. Int J Clin Oncol 2008;13:132-137. (Pubitemid 351668170)
2. MacDonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared withsurgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-727. (Pubitemid 34936653)
3. Yonemura Y, Endou Y, Bando E, et al.: The usefulness of oral TS-1 treatment for potentially curable gastric cancer patients with intraperitoneal free cancer cells. Cancer Therapy 2006;4:135-142.
4. Yonemura Y, Kawamura T, Bandou E, et al.: The natural history of free cancer cells in the peritoneal cavity. In: Gonzalez-Moreno S, editor. Advances in peritoneal surface oncology. Berlin: Springer; 2007. pp. 11-23.
5. Chu DZJ, Lang NP, Thompson C, et al.: Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989;63:364-367.
6. Sadeghi B, Arvieux C, Glehen O, et al.: Peritoneal carcinomatosis from non gynecologic malignancies: Results of the EVOCAPE a multicentric prospective study. Cancer 2000;88:358-363. (Pubitemid 30051820)
7. Sugarbaker PH, Yonemura Y: Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: Best palliation with a ray of hope of cure. Oncology 2000;58:96-107.
8. Yonemura Y, Bandou E, Kinoshita K, et al.: Effective therapy for peritoneal dissemination in gastric cancer. Surg Oncol Clin N Am 2003;12:635-648. (Pubitemid 36920090)
9. Benevolo M, Mottolese M, Coamelli M, et al.: Diagnostic and prognostic value of peritoneal immunocytology in gastric cancer. J Clin Oncol 1998;16:3406-3411. (Pubitemid 28481640)
10. MacDonald JS, Philip SS, Woolley PV, et al.: 5-Fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 1980;93:533-536. (Pubitemid 10015173)
11. Wils JA, Klein HO, Wagener DJ, et al.: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;9:827-831.
12. Ajani JA: Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction. Cancer 2008;113:945-955.
13. Shirasaka T, Nakano K, Takechi H, et al.: Antitumor activity of 1M tegaful,-0.4M 5-chrolo-2,4-dyhydroxypiridine-1M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996;56:2602-2606. (Pubitemid 26171684)
14. Tatsumi K, Fukushima M, Shirasaka T, et al.: Inhibitory effect of pyrimidine, barbituric acid and pyrimidine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987;78:748-755. (Pubitemid 17132408)
15. Yonemura Y, Endou Y, Tochiori S, et al.: Effect of intraperitoneal chemotherapy on experimental peritoneal dissemination of gastric cancer. Gan To Kagaku Ryoho 2005;32:1635-1639.
16. Baba H, Yamamoto M, Endo K, et al.: Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. Gastric Cancer 2003;6:45-49. (Pubitemid 36604656)
17. Jacquet P, Sugarbaker PH: Peritoneal-plasma barrier. In: Sugarbaker PH, editor. Peritoneal carcinomatosis: Principles of management, Boston: Kluwar Academic Publishers; 1996. pp. 53-63.
18. Markman M: Intraperitoneal chemotherapy. Semin Oncol 1991;18:248-254.
19. Los G, Mutsaers PHA, van der Vijgh WJ, et al.: Direct diffusion of cis-diamminedichloroplatinum (II) in intraoeritoneal rat tumors after intraperitoenal chemotherapy: A comparison with systemic chemotherapy. Cancer Res 1989;49:3380-3384. (Pubitemid 19162154)
20. Fushida S, Furui N, Kinami S, et al.: Pharmacologic study of intraperitoneal paclitaxel in gastric cancer patients with peritoneal dissemination. Jpn J Cancer Chemother 2002;29:2164-2167.
21. Marchettini P, Stuart A, Mohamed F, et al.: Docetaxel: Pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. Cancer Chemother Parmacol 2002;49:499-503. (Pubitemid 34671286)
22. Shimada T, Nomura M, Yokogawa K, et al.: Pharamacokineic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice. J Pharm Pharmacol 2005 57:177-181. (Pubitemid 40129084)
23. De Bree EE, Tsiftsis DD: Experimental and pharmacologic studies in intraperitoneal chemotherapy from laboratory bench to bedside. In: Gonzalez-Moreno S, editor. Advances in peritoneal surface oncology. Berlin: Springer; 2007. pp. 53-73.
24. van Tellingen O, Beijnen JH, Verweij J, et al.: Rapid esterase-sensitive breakdown of polysorbete 80 and its impact on the lasma pharmacokinetics of docetaxel and metabolites in mice. Clin Cancer Res 1999;5:2918-2924. (Pubitemid 29493971)
25. Yoshida K, Touge T: Combination chemotherapy of TS-1 and docetaxel on advanced and recurrent gastric cancer. Jpn J Cancer Chemother 2004;31:1982-1986.
26. Nakagawa M, Ninomiya M, Fujita I, et al.: Repeated intraperitoneal injection of low-dose CDDP for gastric cancer with ascites owing to peritonitis carcinomatosa. Gan To Kagaku Ryoho 2002;29:2346-2349.
27. Tanaka M, Obata T, Sasaki T: Evaluation of antitumor effects of Docetaxel (Taxotere) on human gastric cancers in vitro and in vivo. Eur J Cancer 1996;32:226-230. (Pubitemid 26090114)
28. Glehen O, Schreiber V, Cotte E, et al.: Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004;139:20-26. (Pubitemid 38049613)